Trial Profile
Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2014
Price :
$35
*
At a glance
- Drugs AL 78898A (Primary) ; Ranibizumab
- Indications Age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms RACE
- Sponsors Alcon
- 24 Dec 2014 New trial record